20-F/A: Fresh2 Group Faces Going Concern Doubts Amid Business Transition and Regulatory Scrutiny

Fresh2 Group Limited's amended 20-F filing reveals concerns about its ability to continue as a going concern due to recurring losses, working capital deficiency, and a shift towards a new e-commerce food business model.

Summary

• Fresh2 Group Limited is amending its annual report on Form 20-F to disclose risks related to enforcing civil liabilities against its officers and directors in the U.S.
• The company is transitioning from early cancer screening to a B2B e-commerce platform focused on Asian food suppliers.
• Fresh2 Group Limited faces significant uncertainties regarding its ability to continue as a going concern due to recurring losses and a working capital deficit.
• The company plans to address cash flow deficiencies through new revenue sources and additional financing.
• The company's independent auditors have raised substantial doubt about its ability to continue as a going concern.
• The company is subject to complex and evolving PRC and international laws and regulations, increasing operational costs.
• The company identified three material weaknesses in its internal control over financial reporting.
• The company is exposed to risks related to natural disasters, health epidemics, and geopolitical events.
• The company's ability to grow its CDA business depends on penetrating the Chinese hospital market.
• The company faces intense competition in the cancer screening and detection market.
• The company relies on third-party suppliers, sales agents, service providers, and research partners.
• The company is in the early stages of developing its e-commerce food-related business.
• The company faces risks related to food safety, commodity prices, and supply chain disruptions in its e-commerce business.
• The company is required to comply with food safety laws and regulations in the PRC.
• The company is subject to the filing requirements with the CSRC for follow-on overseas offerings.
• The company is subject to U.S. federal and state healthcare fraud and abuse laws.
• The company may be prohibited from listing its securities if it fails to meet audit requirements under the HFCAA.
• The company's dual-class share structure limits shareholders' ability to influence corporate matters.
• The company does not expect to pay dividends in the foreseeable future.
• The company may have difficulty enforcing judgments against its directors and officers.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with significant risks and uncertainties, including going concern doubts, material weaknesses in internal controls, and regulatory challenges. While there are some positive aspects, the overall sentiment is negative.

Positives

• The company is transitioning to a new business model with potential for growth in the Asian e-commerce food market.
• The company is taking steps to remediate material weaknesses in its internal control over financial reporting.
• The company has secured agreements for additional financing to support its operations.
• The company has a comprehensive B2B e-commerce platform.
• The company has a large test database.

Negatives

• The company's independent auditors have raised substantial doubt about its ability to continue as a going concern.
• The company has incurred losses each year since its inception and expects to continue to incur losses.
• The company has a working capital deficit.
• The company identified three material weaknesses in its internal control over financial reporting.
• The company is subject to complex and evolving PRC and international laws and regulations, increasing operational costs.
• The company's ability to grow its CDA business depends on penetrating the Chinese hospital market.
• The company relies on third-party suppliers, sales agents, service providers, and research partners.
• The company is in the early stages of developing its e-commerce food-related business.
• The company is required to comply with food safety laws and regulations in the PRC.
• The company is subject to the filing requirements with the CSRC for follow-on overseas offerings.
• The company is subject to U.S. federal and state healthcare fraud and abuse laws.
• The company may be prohibited from listing its securities if it fails to meet audit requirements under the HFCAA.
• The company's dual-class share structure limits shareholders' ability to influence corporate matters.
• The company does not expect to pay dividends in the foreseeable future.

Risks

• The company may not be able to raise sufficient capital on acceptable terms.
• The company's new business model may not be successful.
• The company's financial condition and results of operations may be adversely affected by government control over capital investments or changes in tax regulations.
• The company's ability to offer securities to investors may be limited by PRC government actions.
• The company may be subject to fines and other sanctions for failure to comply with PRC laws and requirements.
• The company may be unable to protect its intellectual property.
• The company may be subject to liability claims for defective services provided by third-party physical checkup centers.
• The company may be unable to support demand for its cancer screening and detection tests.
• The company may be unable to attract and retain qualified key management, scientists, staff and consultants.
• The company's businesses may be affected by the impacts of unfavorable geopolitical events or other market disruptions on consumer confidence and spending patterns.
• The company has a limited amount of financial resources and its ability to make additional acquisitions without securing additional financing from outside sources is limited.
• The company may be subject to litigation and other claims and legal proceedings, and may not always be successful in defending ourselves against these claims or proceedings.
• The company has limited business insurance coverage.
• The company's business has been affected and may in the future be affected by steps taken by the Chinese government to address the COVID-19 pandemic.
• The food service industry is characterized by low margins, and periods of significant or prolonged inflation or deflation will affect our product and operational costs, which may negatively impact our profitability.
• Unfavorable macroeconomic conditions in the U.S. may adversely affect our business, financial condition and results of operations.
• The geographic concentration of our operations in the United States creates an exposure to economic conditions in the United States and any financial downturn in the United States could materially adversely affect our financial condition and results of operations.
• Competition may increase intensively in the future, which may adversely impact our margins and ability to retain customers, and make it difficult to maintain our market share, growth rate and profitability.
• Increased commodity prices and availability may impact profitability.
• We may not be able to fully compensate for increases in fuel costs when fuel prices experience high volatility, and our operating results would be adversely affected.
• Disruption of relationships with vendors could negatively affect our business.
• Our relationships with customers may be materially diminished or terminated.
• We may fail to increase or maintain the highest margin portions of our business, including sales to restaurant and supermarket customers.
• Changes in consumer eating habits could materially and adversely affect our business, financial condition, and results of operations.
• We engage in transactions with related parties and such transactions present possible conflicts of interest that could have an adverse effect on us.
• We may be unable to protect or maintain our intellectual property, which could result in customer confusion, a negative perception of our brand and adversely affect our business.
• If we are unable to renew or replace our current leases on favorable terms, or any of our current leases are terminated prior to expiration of their stated terms, and we cannot find suitable alternate locations, our operations and profitability could be negatively impacted.
• Failure to retain our senior management and other key personnel may adversely affect our operations.
• If we are unable to attract, train and retain employees, we may not be able to grow or successfully operate our business.
• Changes in and enforcement of immigration laws could increase our costs and adversely affect our ability to attract and retain qualified employees.
• Potential labor disputes with employees and increases in labor costs could adversely affect our business.
• If we fail to comply with requirements imposed by applicable law and other governmental regulations, we could become subject to lawsuits, investigations and other liabilities and restrictions on our operations that could significantly and adversely affect our business.
• If the products distributed by us are alleged to have caused injury or illness, or to have failed to comply with governmental regulations, we may need to recall our products and may experience product liability claims.
• The U.S. government is currently imposing increased tariffs on certain products imported into the U.S., including products imported from China, which may have an adverse impact on our future operating results.
• The filing with the CSRC is required in connection with our follow-on overseas offerings under PRC law, and we cannot predict whether or for how long we will be able to complete such filing.
• As a biotechnology company, we are required to comply with extensive regulations and obtain and maintain a number of permits and licenses to carry on our business in China; future government regulation may place additional burdens on our efforts to commercialize our cancer screening and detection tests and device.
• If we are unable to maintain our medical device or laboratory related licenses and certificates, our growth strategy may be compromised.
• Any change in the regulations governing the use of personal data in China, which are still under development, or any data leakage or unauthorized use of data by third parties could adversely affect our business and reputation.
• Our e-commerce business has a R&D center in China, which is facing various risks.
• Our e-commerce food business plans to source goods globally, including from China, which has inherent risks.
• Our biotechnology business is heavily regulated, and changes in regulations or violations of regulations may, directly or indirectly, reduce our revenue, adversely affect our results of operations and financial condition and harm our business.
• We plan to market our CDA test initially as an LDT, and future changes in the FDAs regulation of LDTs could subject our operations to much more significant regulatory requirements.
• Our proprietary CDA device is an analytical instrument used as part of our CDA test, which may increase our risk that the FDA concludes that our test does not qualify as an LDT.
• Failure to comply with U.S. federal or state laboratory licensing requirements and the applicable requirements of the FDA or any other regulatory authority or accrediting body, could cause us to lose the ability to perform testing in the United States, experience disruptions to our business, or become subject to administrative or judicial sanctions.
• If we are unable to obtain or maintain regulatory clearance or approvals in the United States, or if we experience delays in receiving clearance or approvals, our growth strategy may not be successful.
• Clinical studies involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
• If we receive FDA clearance, marketing authorization, or approval of our CDA device and test, we will continue to be subject to extensive FDA regulatory oversight.
• Our employees may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, and insider trading.
• If we fail to comply with healthcare laws and regulations, we could face substantial enforcement actions, including civil and criminal penalties and our business, operations and financial condition could be adversely affected.
• We could be subject to healthcare fraud and abuse laws and patient privacy laws of both the U.S. federal government and the states in which we conduct our business.
• We may be exposed to liabilities under the United States Foreign Corrupt Practices Act, or FCPA, and Chinese anti-corruption laws, and any determination that we have violated these laws could have a material adverse effect on our business or our reputation.
• The new business requires us to maintain food safety and quality globally, including in China. Any failure to maintain food safety and quality could adversely impact our reputation, results of operations and financial performance.
• We may be adversely affected by the complexity, uncertainties and changes in PRC laws and regulations of E-Commence and Internet-related businesses and companies, and any lack of requisite approvals, licenses or permits applicable to our business may have a material adverse effect on our business and results of operations.
• We are subject to many of the economic and political risks associated with emerging markets due to our operations in China.
• Any change in the regulations governing the use of personal data in China, which are still under development, or any data leakage or unauthorized use of data by third parties could adversely affect our business and reputation.
• Our e-commerce business has a R&D center in China, which is facing various risks.
• Our e-commerce food business plans to source goods globally, including from China, which has inherent risks.
• If for any reason we were to fail to meet the audit requirements of the HFCAA for two consecutive years, we may be prohibited from listing our securities on a national securities exchange, including Nasdaq, or on over-the-counter markets in the United States, which could adversely affect the market price of our Common Stock and our ability to raise capital.
• We have had a history of losses and our ability to grow sales and achieve profitability are unpredictable.
• The impairment of intangible assets and goodwill arising from our acquisitions could continue to negatively impact affect our net income and shareholders equity
• Changes in the political and economic policies of the PRC government or in relations between China and the United States or other governments may materially and adversely affect our business, financial condition, and results of operations and may result in our inability to sustain our growth and expansion strategies.
• The Nasdaq Capital Market imposes listing standards on our ADSs that we may not be able to fulfill, thereby leading to a possible delisting of our ADSs.
• The trading price of our ADSs may be volatile regardless of our operating performance.
• Our dual-class share structure with different voting rights will limit your ability to influence our corporate matters and could discourage others from pursuing any change of control transactions that holders of our Class A ordinary shares and ADSs may view as beneficial.
• Share ownership has remained as of the date of this annual report, and will remain, concentrated in the hands of our principal shareholders and management, who are and will continue to be able to exercise a direct or indirect controlling influence on us.
• If securities or industry analysts do not publish research about our business, or if they adversely change their recommendations regarding our ADSs, the market price for our ADSs and trading volume could decline.
• Substantial future sales or perceived potential sales of ADSs in the public market, including upon the exercise of vested options and conversion of convertible securities, could cause the price of ADSs to decline.
• Our memorandum and articles of association contain anti-takeover provisions that could have a material adverse effect on the rights of holders of our ordinary shares and ADSs.
• As we do not expect to pay dividends in the foreseeable future, you must rely on price appreciation of our ADSs for return on your investment.
• You may not receive dividends or other distributions on our Class A ordinary shares and you may not receive any value for them, if it is illegal or impractical to make them available to you.
• The voting rights of holders of ADSs are limited by the terms of the deposit agreement, and you may not be able to exercise your right to direct the voting of the underlying Class A ordinary shares which are represented by your ADSs.
• You may experience dilution of your holdings due to the inability to participate in rights offerings.
• You may be subject to limitations on transfer of your ADSs.
• Your rights to pursue claims against the depositary as a holder of ADSs are limited by the terms of the deposit agreement.
• We are subject to liability risks stemming from our foreign status, which could make it more difficult for investors to sue or enforce judgments against our company, and the ability of U.S. authorities to bring actions against us or our management may also be limited.
• You may have difficulty enforcing judgment against us or our directors and officers.
• We will incur increased costs as a result of being a public company, particularly after we cease to qualify as an emerging growth company.
• We are a foreign private issuer within the meaning of the rules under the Exchange Act, and as such we are exempt from certain provisions applicable to United States domestic public companies.
• There can be no assurance that we will not be a passive foreign investment company, or PFIC, for U.S. federal income tax purposes for any taxable year, which could subject U.S. Holders of our Class A ordinary shares or ADSs to adverse U.S. federal income tax consequences.

Future Outlook

The company expects to need additional fundraising if its cash flows generated from operations do not increase substantially and intends to finance its future working capital requirements and capital expenditures from cash generated from funds raised from financing activities until operating activities generate positive cash flows, if ever.

Industry Context

The company is operating in the biotechnology and e-commerce sectors, both of which are subject to rapid technological advancements, evolving regulatory landscapes, and intense competition. The company's success depends on its ability to adapt to these changes and maintain a competitive edge.

Comparison to Industry Standards

• The company's CDA technology is positioned as a next-generation cancer screening and detection technology, competing with established methods like imaging and tissue biopsy, as well as other emerging technologies such as CTCs and ct-DNA.
• Competitors in the cancer screening and detection market include BGI in China and GRAIL, Guardant Health, and Exact Sciences worldwide.
• The company's e-commerce food business operates in the fragmented and highly competitive foodservice distribution industry in the United States, facing competition from national, regional, and local distributors.
• The company's financial performance is compared to industry standards in terms of gross profit margins, operating expenses, and research and development spending.

Management Changes

Legal Proceedings

• Three investors filed an action against the company in the State of Delaware Court of Chancery, Chen Wenge, et al. v. Fresh2 Group Limited, C.A. No. 2022-0779-PAF.
• The Plaintiffs sued the Company for breaches of the investment agreements of May 2022.
• The Court issued a temporary restraining order concerning enforcement of the private placements on September 3, 2022, amended the temporary restraining order on September 9, 2022, and further amended the temporary restraining order on September 23, 2022 (TRO).
• In order to settle the Action, on October 15, 2022, the Company entered into Stock Repurchase Agreement with the Plaintiffs and all other investors in the May 2022 private placements with the original investment of $3 million, who beneficially owned an aggregate of 12,492,283 ordinary shares (Shares) of the Company and warrants to purchase a total of 2,475,000 ordinary shares at various exercise prices (the Warrants, together with the Shares, the Securities), for total consideration of $1.5 million.
• The Company fully settled the Action by October 27, 2022.
• In connection with the settlement, by November 7, 2022, Yuyang Cui and Jiawen Kang resigned from the Board of Directors and Yuyang Cui resigned as co-CEO of the Company.
• The related warrants bought back were fully canceled and the ordinary shares bought back become the Companys treasury shares.

Related Party Transactions

• The company has in the ordinary course of its business engaged certain of its investee companies, including AnPac Beijing Health Management Co., Ltd., Jiangsu Anpac and Anpai (Shanghai) Health Management Consulting Co., Ltd., as sales agents for our CDA-based tests.
• In 2021 and 2022, the company incurred a consultancy fee of RMB2,190,000 and RMB2,739,000 (US$397,000) to AnPac Beijing Health Management Co., Ltd. for its marketing services to us.
• In 2021 and 2022, the company recognized service revenue from Annadi Life Therapeutics Co., Ltd. of RMB 1,284,000 and RMB 2,186,000 (US$317,000).
• In 2021 and 2022, the company recognized rendered from Jiangsu Anpac of RMB121,000 and RMB 9,000(US$1,000).
• In 2021 and 2022, the company recognized a rent from Shanghai Muqing Industrial of RMB411,000 and rent reimbursement of RMB32,000 (RMB5,000).
• In 2021, the company incurred a consultancy fee of RMB129,000 to Anpai (Shanghai) Health Management Consulting Co., Ltd.
• In the years ended December 31, 2022 and 2021, the company repaid RMB2,071,00

Next Steps

• The company intends to finance its future working capital requirements and capital expenditures from cash generated from funds raised from financing activities until operating activities generate positive cash flows, if ever.
• The company expects to complete the measures discussed above and also to take actions to (i) continue to recruit experienced personnel with relevant past experience working on U.S. GAAP and SEC reporting, (ii) improve monitoring and oversight controls for non-recurring and complex transactions to ensure the accuracy and completeness of financial reporting and (iii) engage external experts to assist in non-recurring and complex transactions by the end of 2022 and will continue to implement measures to remediate our internal control deficiencies.

Key Dates

Keywords

Fresh2 Group, going concern, financial reporting, risk factors, e-commerce, cancer screening, PRC regulations, ADS, HFCAA, financial statements